Effects of Teriparatide in Postmenopausal Women With Osteoporosis

Effects of Teriparatide in Postmenopausal Women With Osteoporosis Previously Treated With Alendronate or Raloxifene

Effects of Teriparatide in Postmenopausal Women Previously Treated with Alendronate or Raloxifene.

Inclusion Criteria:

• Postmenopausal women aged at least 50 years
• A previous clinical diagnosis of osteoporosis
• At high risk for fracture
• Current therapy for at least 18 months prior to study entry with either raloxifene HCl or alendronate Na

Exclusion Criteria:

• History of metabolic bone disease other than osteoporosis
• History of malignant neoplasm within the last 5 years except for superficial basal cell carcinoma or squamous cell carcinoma